To date, four clinical trials involving children affected by NB and nine in glioblastoma patients are currently ongoing using anti-CTLA-4 antibodies in combination with standard therapies or other drugs (www.clinicaltrials.gov, accessed on 28 March 2021). The gene discussed is CTLA4; the disease is glioblastoma.